Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis
Journal of Nephropathology · 05.02.2023
DOI: 10.34172/jnp.2023.21444 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Nephropathology, online erschienen am 05.02.2023. Verfasst von Mobin Mohammadtabar und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigate the relationship between SGLT2 inhibitors and BC in patients with T2D. Materials and Methods: This study is a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). International databases including Cochrane, Web of Science, Scopus, PubMed, and Google Scholar were conducted for searching with keywords and without time and language limitations. The reference searching stage continued upgrading until November, 2022. Data analysis was performed with STATA 14 software. The tests with P values lower than 0.05 were considered statistically significant.
Results
The four reviewed studies with a sample size comprising 497 755 individuals indicated the impact of SGLT2 inhibitors on BC of patients with T2D (OR: 0.68; 95% CI: 0.37, 1.2). The effect of dapagliflozin, canagliflozin and empagliflozin administration on the incidence of BC among the T2D patients were (OR: 0.72; 95% CI: 0.39, 1.30), (OR: 0.53; 95% CI: 0.23, 1.20), and (OR: 0.51; 95% CI: 0.20, 1.28), respectively.
Conclusion
The general conclusion of this study revealed that SGLT2 inhibitors did not increase the risk of BC in T2D patients. The analysis of subgroups also indicated that the administration of dapagliflozin, canagliflozin, and empagliflozin also did not increase the risk of BC in T2D patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID=CRD42023389014).
Zitieren
APA
Mohammadtabar, M., Fazeli, A., Parsai, N., Aboulfathiyarmohammadyar, Z., Shafiei, E., Khaledi, M., Zaremoghadam, E., Sisakht, A. R., Mohammadi, S., & Mardanparvar, H. (2023). Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis. Journal of Nephropathology. https://doi.org/10.34172/jnp.2023.21444
Vancouver
Mohammadtabar M, Fazeli A, Parsai N, Aboulfathiyarmohammadyar Z, Shafiei E, Khaledi M, et al. Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis. Journal of Nephropathology. 2023. doi:10.34172/jnp.2023.21444
BibTeX
@article{Mohammadtabar2023,
author = {Mohammadtabar, Mobin and Fazeli, Alireza and Parsai, Najmeh and Aboulfathiyarmohammadyar, Zahra and Shafiei, Erfan and Khaledi, Mohamad and Zaremoghadam, Elahe and Sisakht, Ali Rahnama and Mohammadi, Saeid and Mardanparvar, Hossein},
title = {Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis},
journal = {Journal of Nephropathology},
year = {2023},
doi = {10.34172/jnp.2023.21444}
}
EUVIMED